drugset / Trial / NCT06924970
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2026-05
- Completion
- 2027-05
Outcome
Met primary endpoint
release “The trial’s primary endpoint of hemoglobin response (≥1.0 g/dL increase in average hemoglobin concentration from Weeks 10 through 12 compared with baseline) was achieved” agios.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tebapivat | Small molecule | 2.5 mg | Oral |
| Subject | Tebapivat | Small molecule | 5 mg | Oral |
| Subject | Tebapivat | Small molecule | 7.5 mg | Oral |